Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

NCT04371978 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

64

Enrollment

OTHER

Sponsor class

Stopped End of COVID-19 outbreak in Israel

Conditions

COVID 19
Coronavirus
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Disease
Endocrine System Diseases
Dipeptidyl-Peptidase IV Inhibitors
Linagliptin
Severe Acute Respiratory Syndrome Coronavirus 2
Sars-CoV2
Hypoglycemic Agents
Respiratory Tract Diseases
Incretins
Hormones

Interventions

DRUG: Linagliptin 5 MG

Sponsor

Rabin Medical Center